| 2026 |
| 03/06 | 3,685 | 3,715 | 3,660 | 3,690 | -1.34% | 23,700 | 1342億7910万 | -1.7% |
| 03/05 | 3,765 | 3,795 | 3,710 | 3,740 | +1.22% | 30,000 | 1360億9860万 | -0.24% |
| 03/04 | 3,695 | 3,715 | 3,610 | 3,695 | -2.89% | 44,100 | 1344億6105万 | -1.31% |
| 03/03 | 3,875 | 3,880 | 3,800 | 3,805 | -2.93% | 41,500 | 1384億6395万 | +1.66% |
| 03/02 | （IR情報）15:00 ベトナムにおけるエパデール発売のお知らせ |
| 03/02 | （IR情報）14:00 人事異動のお知らせ |
| 03/02 | 3,925 | 3,950 | 3,885 | 3,920 | -1.13% | 33,400 | 1426億4880万 | +4.78% |
| 02/27 | 3,855 | 3,965 | 3,855 | 3,965 | +1.67% | 46,700 | 1442億8635万 | +6.27% |
| 02/26 | 3,910 | 3,925 | 3,840 | 3,900 | 0% | 43,700 | 1419億2100万 | +4.87% |
| 02/25 | 3,865 | 3,910 | 3,850 | 3,900 | +1.17% | 45,300 | 1419億2100万 | +5.15% |
| 02/24 | 3,800 | 3,885 | 3,765 | 3,855 | +1.98% | 23,500 | 1402億8345万 | +4.19% |
| 02/20 | 3,875 | 3,875 | 3,780 | 3,780 | -2.58% | 23,100 | 1375億5420万 | +2.36% |
| 02/19 | 3,850 | 3,900 | 3,795 | 3,880 | +0.78% | 48,100 | 1411億9320万 | +5.12% |
| 02/18 | 3,710 | 3,865 | 3,710 | 3,850 | +4.9% | 77,300 | 1401億150万 | +4.53% |
| 02/17 | 3,715 | 3,745 | 3,670 | 3,670 | -1.21% | 32,300 | 1335億5130万 | -0.11% |
| 02/16 | 3,745 | 3,750 | 3,675 | 3,715 | -0.4% | 23,100 | 1351億8885万 | +1.17% |
| 02/13 | 3,770 | 3,780 | 3,685 | 3,730 | -0.4% | 22,900 | 1357億3470万 | +1.63% |
| 02/12 | 3,785 | 3,785 | 3,745 | 3,745 | 0% | 30,400 | 1362億8055万 | +2.15% |
| 02/10 | 3,760 | 3,790 | 3,725 | 3,745 | +0.4% | 32,600 | 1362億8055万 | +2.38% |
| 02/09 | 3,790 | 3,790 | 3,705 | 3,730 | +2.19% | 82,200 | 1357億3470万 | +2.19% |
| 02/06 | （IR情報）14:00 業績予想の修正に関するお知らせ |
| 02/06 | （IR情報）14:00 2026年3月期第3四半期決算短信〔日本基準〕(連結) |
| 02/06 | （IR情報）14:00 造血幹細胞移植後の非感染性肺合併症に対する臍帯由来間葉系間質細胞「HLC-001」第III相臨床試験治験計画届の提出に関するお知らせ |
| 02/06 | （IR情報）14:00 Mochida Medical USA, Inc. 設立のお知らせ |
| 02/06 | 3,720 | 3,795 | 3,635 | 3,650 | -2.54% | 104,500 | 1328億2350万 | +0.22% |
| 02/05 | 3,745 | 3,785 | 3,735 | 3,745 | +0.94% | 37,000 | 1362億8055万 | +3.03% |
| 02/04 | 3,685 | 3,755 | 3,660 | 3,710 | +1.09% | 52,200 | 1350億690万 | +2.4% |
| 02/03 | 3,635 | 3,710 | 3,635 | 3,670 | +1.8% | 41,000 | 1335億5130万 | +1.61% |
| 02/02 | 3,620 | 3,675 | 3,595 | 3,605 | -0.41% | 35,100 | 1311億8595万 | +0.06% |
| 01/30 | 3,565 | 3,625 | 3,555 | 3,620 | +2.12% | 37,400 | 1317億3180万 | +0.7% |
| 01/29 | 3,515 | 3,545 | 3,455 | 3,545 | -0.14% | 36,800 | 1290億255万 | -1.12% |
| 01/28 | 3,605 | 3,605 | 3,540 | 3,550 | -2.07% | 34,500 | 1291億8450万 | -0.84% |
| 01/27 | 3,635 | 3,635 | 3,600 | 3,625 | -1.36% | 30,400 | 1319億1375万 | +1.34% |
| 01/26 | 3,675 | 3,725 | 3,655 | 3,675 | -1.74% | 33,000 | 1337億3325万 | +2.97% |
| 01/23 | 3,675 | 3,740 | 3,670 | 3,740 | +1.91% | 32,000 | 1360億9860万 | +5.09% |
| 01/22 | 3,670 | 3,725 | 3,650 | 3,670 | +0.14% | 24,700 | 1335億5130万 | +3.5% |
| 01/21 | （IR情報）14:00 頭皮の悩みに、メディカル発想でひとつ上の答えを！「コラージュフルフルプラスシリーズ」新発売 |
| 01/21 | 3,625 | 3,665 | 3,620 | 3,665 | +0.41% | 29,500 | 1333億6935万 | +3.68% |
| 01/20 | 3,660 | 3,675 | 3,625 | 3,650 | -0.82% | 22,200 | 1328億2350万 | +3.55% |
| 01/19 | 3,695 | 3,715 | 3,675 | 3,680 | -0.27% | 20,800 | 1339億1520万 | +4.63% |
| 01/16 | 3,675 | 3,700 | 3,635 | 3,690 | -0.94% | 31,200 | 1342億7910万 | +5.28% |
| 01/15 | 3,685 | 3,725 | 3,635 | 3,725 | +1.64% | 42,000 | 1355億5275万 | +6.73% |
| 01/14 | 3,600 | 3,710 | 3,600 | 3,665 | +0.96% | 47,500 | 1333億6935万 | +5.53% |
| 01/13 | （IR情報）14:00 人事異動のお知らせ |
| 01/13 | 3,660 | 3,675 | 3,605 | 3,630 | +0.41% | 35,100 | 1320億9570万 | +4.94% |
| 01/09 | 3,670 | 3,690 | 3,605 | 3,615 | -1.5% | 35,200 | 1315億4985万 | +4.87% |
| 01/08 | （IR情報）15:00 中国におけるエパデールの新薬承認取得のお知らせ |
| 01/08 | 3,625 | 3,700 | 3,625 | 3,670 | +1.24% | 58,100 | 1335億5130万 | +6.75% |
| 01/07 | 3,535 | 3,675 | 3,535 | 3,625 | +1.68% | 64,100 | 1319億1375万 | +5.75% |
| 01/06 | 3,540 | 3,565 | 3,510 | 3,565 | +0.71% | 40,900 | 1297億3035万 | +4.15% |
| 01/05 | 3,545 | 3,585 | 3,505 | 3,540 | +0.14% | 41,400 | 1288億2060万 | +3.63% |
| 2025 |
| 12/30 | 3,600 | 3,610 | 3,515 | 3,535 | +1.87% | 57,200 | 1286億3865万 | +3.57% |
| 12/29 | 3,450 | 3,470 | 3,435 | 3,470 | +0.73% | 32,700 | 1262億7330万 | +1.79% |
| 12/26 | 3,460 | 3,460 | 3,420 | 3,445 | +0.44% | 20,700 | 1253億6355万 | +1.2% |
| 12/25 | 3,405 | 3,435 | 3,405 | 3,430 | -0.15% | 13,000 | 1248億1770万 | +0.91% |
| 12/24 | 3,430 | 3,475 | 3,415 | 3,435 | +0.29% | 26,600 | 1249億9965万 | +1.33% |
| 12/23 | 3,355 | 3,440 | 3,350 | 3,425 | +1.93% | 32,200 | 1246億3575万 | +1.18% |
| 12/22 | （IR情報）15:30 世界初、TRPV1拮抗作用を持つドライアイ治療薬「アバレプト懸濁性点眼液0.3%」国内承認取得のお知らせ |
| 12/22 | 3,420 | 3,440 | 3,330 | 3,360 | -1.75% | 40,200 | 1222億7040万 | -0.59% |
| 12/19 | 3,455 | 3,490 | 3,415 | 3,420 | -1.87% | 45,800 | 1244億5380万 | +1.3% |
| 12/18 | 3,430 | 3,500 | 3,430 | 3,485 | +2.35% | 25,000 | 1268億1915万 | +3.5% |
| 12/17 | 3,480 | 3,490 | 3,400 | 3,405 | -1.16% | 34,500 | 1239億795万 | +1.55% |
| 12/16 | 3,415 | 3,455 | 3,395 | 3,445 | +1.32% | 33,100 | 1253億6355万 | +3.11% |
| 12/15 | （IR情報）14:00 妊娠時の悪心・嘔吐治療剤「Bonjesta」の日本国内における開発および販売に関する契約締結のお知らせ |
| 12/15 | 3,375 | 3,430 | 3,375 | 3,400 | -0.29% | 13,700 | 1237億2600万 | +2.19% |
| 12/12 | 3,440 | 3,465 | 3,370 | 3,410 | +0.29% | 33,000 | 1240億8990万 | +2.87% |
| 12/11 | 3,425 | 3,450 | 3,400 | 3,400 | -1.31% | 16,300 | 1237億2600万 | +2.97% |
| 12/10 | （IR情報）14:00 人事異動のお知らせ |
| 12/10 | 3,395 | 3,460 | 3,385 | 3,445 | +1.92% | 19,100 | 1253億6355万 | +4.81% |
| 12/09 | 3,320 | 3,390 | 3,320 | 3,380 | +1.81% | 18,100 | 1229億9820万 | +3.33% |
| 12/08 | 3,340 | 3,355 | 3,315 | 3,320 | +0.45% | 22,400 | 1208億1480万 | +2.03% |
| 12/05 | 3,300 | 3,340 | 3,295 | 3,305 | -0.45% | 20,600 | 1202億6895万 | +2.04% |
| 12/04 | 3,325 | 3,345 | 3,300 | 3,320 | -0.15% | 33,000 | 1208億1480万 | +2.95% |
| 12/03 | 3,355 | 3,375 | 3,325 | 3,325 | -1.77% | 47,300 | 1209億9675万 | +3.49% |
| 12/02 | 3,405 | 3,420 | 3,360 | 3,385 | -1.31% | 32,600 | 1231億8015万 | +5.65% |
| 12/01 | （IR情報）14:00 軟骨修復材 モチジェルの保険適用ならびに新発売のお知らせ |
| 12/01 | 3,490 | 3,490 | 3,395 | 3,430 | -1.86% | 34,100 | 1248億1770万 | +7.46% |
| 11/28 | 3,420 | 3,500 | 3,420 | 3,495 | +2.95% | 37,200 | 1271億8305万 | +9.97% |
| 11/27 | 3,425 | 3,430 | 3,385 | 3,395 | -2.02% | 20,800 | 1235億4405万 | +7.44% |
| 11/26 | 3,460 | 3,495 | 3,425 | 3,465 | +1.17% | 40,900 | 1260億9135万 | +10.07% |
| 11/25 | 3,380 | 3,445 | 3,350 | 3,425 | +1.93% | 58,400 | 1246億3575万 | +9.32% |
| 11/21 | 3,270 | 3,360 | 3,270 | 3,360 | +1.82% | 50,100 | 1222億7040万 | +7.76% |
| 11/20 | 3,225 | 3,305 | 3,215 | 3,300 | +2.8% | 37,000 | 1200億8700万 | +6.21% |
| 11/19 | 3,285 | 3,305 | 3,200 | 3,210 | -3.17% | 33,400 | 1168億1190万 | +3.65% |
| 11/18 | 3,280 | 3,315 | 3,270 | 3,315 | +0.15% | 40,800 | 1206億3285万 | +7.28% |
| 11/17 | （IR情報）14:00 人事異動のお知らせ |
| 11/17 | 3,240 | 3,325 | 3,240 | 3,310 | +1.69% | 59,200 | 1204億5090万 | +7.47% |
| 11/14 | 3,185 | 3,260 | 3,160 | 3,255 | +2.36% | 46,100 | 1184億4945万 | +5.96% |
| 11/13 | 3,145 | 3,200 | 3,145 | 3,180 | +1.11% | 19,900 | 1157億2020万 | +3.72% |
| 11/12 | 3,130 | 3,180 | 3,130 | 3,145 | +1.13% | 41,300 | 1144億4655万 | +2.61% |
| 11/11 | 3,115 | 3,135 | 3,085 | 3,110 | +0.32% | 32,100 | 1131億7290万 | +1.44% |
| 11/10 | 3,095 | 3,105 | 3,070 | 3,100 | +0.32% | 24,600 | 1128億900万 | +1.08% |
| 11/07 | 3,080 | 3,095 | 3,050 | 3,090 | +0.32% | 20,700 | 1124億4510万 | +0.75% |
| 11/06 | 3,025 | 3,085 | 3,010 | 3,080 | +1.48% | 31,400 | 1120億8120万 | +0.42% |
| 11/05 | 3,040 | 3,105 | 2,987 | 3,035 | -0.33% | 70,900 | 1104億4365万 | -1.14% |
| 11/04 | （IR情報）14:00 2026年3月期第2四半期(中間期)決算短信〔日本基準〕(連結) |
| 11/04 | 2,940 | 3,085 | 2,940 | 3,045 | +3.29% | 124,500 | 1108億755万 | -1.04% |
| 10/31 | 2,997 | 2,997 | 2,936 | 2,948 | -0.14% | 37,900 | 1072億7772万 | -4.5% |
| 10/30 | 2,950 | 2,968 | 2,939 | 2,952 | +0.07% | 41,000 | 1074億2328万 | -4.74% |
| 10/29 | 3,000 | 3,010 | 2,929 | 2,950 | -1.99% | 46,100 | 1073億5050万 | -5.24% |
| 10/28 | 3,095 | 3,095 | 3,010 | 3,010 | -3.37% | 31,800 | 1095億3390万 | -3.68% |
| 10/27 | 3,110 | 3,125 | 3,080 | 3,115 | +1.3% | 21,900 | 1133億5485万 | -0.64% |
| 10/24 | 3,080 | 3,095 | 3,060 | 3,075 | -0.32% | 13,400 | 1118億9925万 | -2.04% |
| 10/23 | 3,075 | 3,120 | 3,075 | 3,085 | +0.98% | 22,200 | 1122億6315万 | -1.88% |
| 10/22 | 3,105 | 3,130 | 3,055 | 3,055 | -0.97% | 33,600 | 1111億7145万 | -3.05% |
| 10/21 | （IR情報）14:00 整形外科領域の医療機器製品に関する業務提携基本契約締結のお知らせ |
| 10/21 | 3,095 | 3,110 | 3,070 | 3,085 | -0.16% | 26,200 | 1122億6315万 | -2.28% |
| 10/20 | 3,085 | 3,090 | 3,060 | 3,090 | +1.31% | 10,700 | 1124億4510万 | -2.28% |
| 10/17 | 3,055 | 3,070 | 3,045 | 3,050 | -0.97% | 12,700 | 1109億8950万 | -3.72% |
| 10/16 | 3,055 | 3,085 | 3,050 | 3,080 | +0.82% | 15,500 | 1120億8120万 | -3.05% |
| 10/15 | 3,065 | 3,090 | 3,030 | 3,055 | +0.66% | 27,600 | 1111億7145万 | -4.08% |
| 10/14 | 3,050 | 3,060 | 3,005 | 3,035 | -0.65% | 29,100 | 1104億4365万 | -4.92% |
| 10/10 | 3,080 | 3,095 | 3,055 | 3,055 | -2.24% | 25,100 | 1111億7145万 | -4.53% |
| 10/09 | 3,100 | 3,135 | 3,100 | 3,125 | +0.48% | 24,200 | 1137億1875万 | -2.5% |
| 10/08 | 3,130 | 3,175 | 3,110 | 3,110 | -1.11% | 19,300 | 1131億7290万 | -3.02% |
| 10/07 | 3,130 | 3,165 | 3,130 | 3,145 | -0.47% | 20,600 | 1144億4655万 | -1.99% |
| 10/01 | （IR情報）13:00 人事異動のお知らせ |
10年以上蓄積したファイナンスデータとAIを掛け合わせて、投資の意思決定を加速させるポジションです。
